| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
5-Methoxyuridine targets RNA metabolism and immune recognition pathways. As a modified nucleoside, the compound can be incorporated into RNA molecules to improve their translation efficiency and reduce immune recognition. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, 5-Methoxyuridine is used as a building block for RNA synthesis. The methoxy modification at the 5-position of the uracil base can affect RNA structure, stability, and interactions with proteins and immune receptors. These properties make the compound useful for the development of mRNA vaccines and other RNA-based therapeutics.
|
| ln Vivo |
In cell-based assays, 5-Methoxyuridine-containing RNA molecules exhibit improved translation efficiency and reduced immune recognition. The modified nucleoside reduces the activation of Toll-like receptors and other immune sensors, allowing for more efficient protein expression from exogenous RNA. These properties are valuable for mRNA vaccine development and RNA therapeutics.
|
| Enzyme Assay |
The cell-free assay for studying 5-Methoxyuridine involves its incorporation into RNA molecules during in vitro transcription. The modified RNA is then used in cell-free translation systems to assess translation efficiency. The effect on immune recognition can be assessed by measuring the activation of purified immune receptors or by using cell-free immune sensing assays.
|
| Cell Assay |
Cell-based assays for 5-Methoxyuridine involve transfecting modified RNA into mammalian cells and measuring protein expression and immune activation. Cells are transfected with 5-methoxyuridine-containing mRNA at concentrations of 0.1-10 μg/mL. Protein expression is measured by Western blotting, ELISA, or flow cytometry. Immune activation is assessed by measuring cytokine production or by analyzing the activation of immune signaling pathways.
|
| Animal Protocol |
In animal models, 5-methoxyuridine-containing mRNA has been evaluated for vaccine efficacy and therapeutic applications. Typical studies involve administration of modified mRNA to mice via intramuscular or intravenous routes. The immunogenicity and therapeutic efficacy are assessed by measuring antibody responses, protein expression, and disease outcomes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5-methoxyuridine itself have not been extensively reported. The pharmacokinetics of 5-methoxyuridine-containing mRNA depend on the formulation and delivery system. Lipid nanoparticle formulations of modified mRNA exhibit distribution to the liver, spleen, and other tissues. The modified nucleoside enhances mRNA stability and reduces immune recognition.
|
| Toxicity/Toxicokinetics |
Toxicity data for 5-methoxyuridine are not well documented. The compound is used as a modified nucleoside in RNA therapeutics and has been shown to reduce immune activation compared to unmodified RNA. Standard toxicity studies would be required for therapeutic applications.
|
| References | |
| Additional Infomation |
5-Methoxyuridine is a derivative of uridine with an additional methoxy substituent at the 5-position of the uracil ring.
5-Methoxyuridine is a research compound used in mRNA vaccines, antisense oligonucleotides, and other RNA-based applications to improve translation efficiency and reduce immune recognition. The compound is a purine nucleoside analog. It is not an approved pharmaceutical but is used in the development of mRNA-based therapeutics and vaccines. This product is intended for research use only. |
| Molecular Formula |
C10H14N2O7
|
|---|---|
| Molecular Weight |
274.23
|
| Exact Mass |
274.08
|
| CAS # |
35542-01-9
|
| Related CAS # |
5-Methoxyuridine-5'-triphosphate; 847649-65-4; 5-Methoxyuridine-d3
|
| PubChem CID |
1265899
|
| Appearance |
White to off-white solid powder
|
| Density |
1.65±0.1 g/cm3(Predicted)
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
424
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
|
| InChi Key |
ZXIATBNUWJBBGT-JXOAFFINSA-N
|
| InChi Code |
InChI=1S/C10H14N2O7/c1-18-4-2-12(10(17)11-8(4)16)9-7(15)6(14)5(3-13)19-9/h2,5-7,9,13-15H,3H2,1H3,(H,11,16,17)/t5-,6-,7-,9-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methoxypyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~182.3 mM; with ultrasonication)
H2O: ~33.3 mg/mL (~121.5 mM; with ultrasonication) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6466 mL | 18.2329 mL | 36.4657 mL | |
| 5 mM | 0.7293 mL | 3.6466 mL | 7.2931 mL | |
| 10 mM | 0.3647 mL | 1.8233 mL | 3.6466 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
